Expertise in
2
conditions

Dr. Darren S. Sigal

Hematology
Scripps Clinic Encinitas-326 Santa Fe
326 Santa Fe Dr, 
Encinitas, CA 
Offers Telehealth
Expertise in
2
conditions
Scripps Clinic Encinitas-326 Santa Fe
326 Santa Fe Dr, 
Encinitas, CA 

Overview

Darren Sigal is a Hematologist practicing medicine in Encinitas, California.

Dr. Sigal is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Intestinal Cancer.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in IL

Hospital Affiliations

Scripps Green Hospital
Scripps Mercy Hospital
Scripps Memorial Hospital - Encinitas
Scripps Memorial Hospital La Jolla

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Scripps Clinic Encinitas-326 Santa Fe
326 Santa Fe Dr, Encinitas, CA 92024
Other Locations
Scripps Clinic Rancho Bernardo
15004 Innovation Dr, San Diego, CA 92128

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Drug, Biological
Study Drugs: CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Study Phase: Phase 1/Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma
A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma
Enrollment Status: Terminated
Publish Date: April 11, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia
A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia
Enrollment Status: Withdrawn
Publish Date: April 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

23 Total Publications

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.
Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.
Journal: The oncologist
Published: March 24, 2026
Similar Doctors
Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Regents Of The University Of California

9400 Campus Point Dr, 
La Jolla, CA 
 (11.4 miles away)
858-822-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Kipps is a Hematologist practicing medicine in La Jolla, California. Dr. Kipps is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Leukemia.

Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Referral may be required

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (18.2 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Geller is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Geller is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Wilms Tumor, Hepatoblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration. Dr. Geller is currently accepting new patients.

Expertise in
33
conditions
Dr. Alan Saven
Hematology
Expertise in
33
conditions
Dr. Alan Saven
Hematology
Referral may be required

Scripps Clinic Torrey Pines

10710 N Torrey Pines Rd, 
La Jolla, CA 
 (9.8 miles away)
858-299-2984
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alan Saven is a Hematologist practicing medicine in La Jolla, California. He has been practicing medicine for over 44 years. Dr. Saven is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Hairy Cell Leukemia (HCL), Hodgkin Lymphoma, Reticuloendotheliosis, and Myelodysplastic Syndrome (MDS).

Frequently Asked Questions about Dr. Darren S. Sigal

How do I make an appointment with Dr. Darren S. Sigal?

You can book an appointment with Dr. Darren S. Sigal by calling their office at 760-753-5594. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Darren S. Sigal a top-rated expert for Pancreatic Ductal Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Darren S. Sigal is classified as an Distinguished expert for Pancreatic Ductal Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Darren S. Sigal specialize in?

While Dr. Darren S. Sigal is a Hematology, they have specific expertise in Pancreatic Ductal Adenocarcinoma, Multiple Myeloma, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Darren S. Sigal participate in research or clinical trials?

Yes. Dr. Darren S. Sigal has published 23 articles and abstracts on conditions like Pancreatic Ductal Adenocarcinoma. You can view a list of Dr. Darren S. Sigal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Darren S. Sigal accept my insurance?

Dr. Darren S. Sigal accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 760-753-5594 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sigal's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile